Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06625749 · ClinicalTrials.gov registry record · NA
Evaluate the Safety and Effectiveness of the AccuraSee™ IOPCL for Secondary Implantation in the Capsular Bag to Improve Near and/or Intermediate Vision Following Previous Cataract Surgery
A NA study of Refractive Surgery and Refractive Error - Myopia, sponsored by OnPoint Vision.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06625749 is a NA study of Refractive Surgery and Refractive Error - Myopia that is actively recruiting participants, run by OnPoint Vision. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06625749, a NA study of Refractive Surgery and Refractive Error - Myopia, is actively recruiting participants, sponsored by OnPoint Vision.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to evaluate the safety and effectiveness of the AccuraSee™ intraocular pseudophakic capsular lens (IOPCL) to improve near and/or intermediate vision following previous cataract surgery.
Conditions Studied
Interventions
- DEVICE Accurasee™ IOPCL
Study Locations (1)
Ohio
- Midwest Vision Partners - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-09-23 |
| Est. Completion | 2026-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06625749
The ClinicalTrials.gov registry entry for NCT06625749 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OnPoint Vision, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Refractive Surgery appearing as the primary indexed condition, and to 1 intervention - of which Accurasee™ IOPCL is the first listed.
NCT06625749 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06625749 about?
NCT06625749 is a clinical study titled "Evaluate the Safety and Effectiveness of the AccuraSee™ IOPCL for Secondary Implantation in the Capsular Bag to Improve Near and/or Intermediate Vision Following Previous Cataract Surgery". This is a study to evaluate the safety and effectiveness of the AccuraSee™ intraocular pseudophakic capsular lens (IOPCL) to improve near and/or intermediate vision following previous cataract surgery.
What is the current status of trial NCT06625749?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2024-09-23. Estimated completion is 2026-03.
What conditions does trial NCT06625749 study?
This clinical trial studies the following conditions: Refractive Surgery, Refractive Error - Myopia.
What interventions are being tested in trial NCT06625749?
The interventions under investigation include: Accurasee™ IOPCL (DEVICE).
Who is sponsoring clinical trial NCT06625749?
This trial is sponsored by OnPoint Vision, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06625749 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractive Surgery
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.